(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.46%) $78.84
(0.36%) $2.20
(0.12%) $2 334.10
(0.28%) $27.69
(0.27%) $967.50
(-0.05%) $0.928
(-0.44%) $10.83
(-0.13%) $0.796
(-0.12%) $91.35
0.00% € 0.000200
Live Chart Being Loaded With Signals
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction...
Stats | |
---|---|
Volumen de hoy | 129.10M |
Volumen promedio | 104.90M |
Capitalización de mercado | 1.48M |
EPS | €0 ( 2024-04-05 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | 0 |
ATR14 | €0 (0.00%) |
Oxurion NV Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Oxurion NV Finanzas
Annual | 2023 |
Ingresos: | €263 000 |
Beneficio Bruto: | €104 000 (39.54 %) |
EPS: | €-0.0115 |
FY | 2023 |
Ingresos: | €263 000 |
Beneficio Bruto: | €104 000 (39.54 %) |
EPS: | €-0.0115 |
FY | 2022 |
Ingresos: | €595 000 |
Beneficio Bruto: | €-271 000 (-45.55 %) |
EPS: | €-0.370 |
FY | 2021 |
Ingresos: | €1.13M |
Beneficio Bruto: | €516 000 (45.74 %) |
EPS: | €-0.928 |
Financial Reports:
No articles found.
Oxurion NV
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico